185 related articles for article (PubMed ID: 38295285)
21. CAR T-Cell-Associated Neurotoxicity: Current Management and Emerging Treatment Strategies.
Rivera AM; May S; Lei M; Qualls S; Bushey K; Rubin DB; Barra ME
Crit Care Nurs Q; 2020; 43(2):191-204. PubMed ID: 32084062
[TBL] [Abstract][Full Text] [Related]
22. CAR t-cell therapy in BOlogNa-NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON-NEUTRAL): proposed protocol and results from an Italian study.
Pensato U; Amore G; Muccioli L; Sammali S; Rondelli F; Rinaldi R; D'Angelo R; Nicodemo M; Mondini S; Sambati L; Asioli GM; Rossi S; Santoro R; Cretella L; Ferrari S; Spinardi L; Faccioli L; Fanti S; Paccagnella A; Pierucci E; Casadei B; Pellegrini C; Zinzani PL; Bonafè M; Cortelli P; Bonifazi F; Guarino M
J Neurol; 2023 May; 270(5):2659-2673. PubMed ID: 36869888
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
Gu T; Hu K; Si X; Hu Y; Huang H
WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
[TBL] [Abstract][Full Text] [Related]
24. Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies.
Dos Santos DMC; Rejeski K; Winkelmann M; Liu L; Trinkner P; Günther S; Bücklein VL; Blumenberg V; Schmidt C; Kunz WG; Von Bergwelt-Baildon M; Theurich S; Subklewe M
Haematologica; 2022 Sep; 107(9):2096-2107. PubMed ID: 35172565
[TBL] [Abstract][Full Text] [Related]
25. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
[TBL] [Abstract][Full Text] [Related]
26. EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome.
Hernani R; Aiko M; Victorio R; Benzaquén A; Pérez A; Piñana JL; Hernández-Boluda JC; Amat P; Pastor-Galán I; Remigia MJ; Ferrer-Lores B; Micó M; Carbonell N; Ferreres J; Blasco-Cortés ML; Santonja JM; Dosdá R; Estellés R; Campos S; Martínez-Ciarpaglini C; Ferrández-Izquierdo A; Goterris R; Gómez M; Teruel A; Saus A; Ortiz A; Morello D; Martí E; Carretero C; Calabuig M; Tormo M; Terol MJ; Cases P; Solano C
Clin Neurophysiol; 2024 Apr; 163():132-142. PubMed ID: 38733703
[TBL] [Abstract][Full Text] [Related]
27. Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.
Schorr C; Forindez J; Espinoza-Gutarra M; Mehta R; Grover N; Perna F
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176053
[TBL] [Abstract][Full Text] [Related]
28. GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients.
Gust J; Rawlings-Rhea SD; Wilson AL; Tulberg NM; Sherman AL; Seidel KD; Wu QV; Park JR; Gardner RA; Annesley CE
Blood Adv; 2023 Mar; 7(6):1001-1010. PubMed ID: 36006611
[TBL] [Abstract][Full Text] [Related]
29. Neuroimaging of complications arising after CD19 chimeric antigen receptor T-cell therapy: A review.
Pinto SN; Liu CJ; Nelson MD; Bluml S; Livingston D; Tamrazi B
J Neuroimaging; 2023; 33(5):703-715. PubMed ID: 37327044
[TBL] [Abstract][Full Text] [Related]
30. Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy.
Zhao Y; Zhang X; Zhang M; Guo R; Zhang Y; Pu Y; Zhu H; Liu P; Zhang Y; He X; Lyu C; Lyu H; Xiao X; Zhao M
Ann Hematol; 2024 Mar; 103(3):969-980. PubMed ID: 38214708
[TBL] [Abstract][Full Text] [Related]
31. Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma.
Barata A; Hoogland AI; Kommalapati A; Logue J; Welniak T; Hyland KA; Eisel SL; Small BJ; Jayani RV; Booth-Jones M; Oswald LB; Gonzalez BD; Kirtane KS; Jain MD; Mokhtari S; Chavez JC; Lazaryan A; Shah BD; Locke FL; Jim HSL
Transplant Cell Ther; 2022 Jul; 28(7):401.e1-401.e7. PubMed ID: 35580732
[TBL] [Abstract][Full Text] [Related]
32. CAR-T Cell Therapy-Related Neurotoxicity in Pediatric Acute Lymphoblastic Leukemia: Spectrum of Imaging Findings.
Tan AP
Pediatr Neurol; 2020 Oct; 111():51-58. PubMed ID: 32951662
[TBL] [Abstract][Full Text] [Related]
33. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].
Du MY; Zhang YQ; Liao DY; Xie W; Xiong W; Mei H; Hu Y
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):793-799. PubMed ID: 38049329
[No Abstract] [Full Text] [Related]
34. Efficacy and safety of CD19 CAR-T cell therapy for patients with B cell acute lymphoblastic leukemia involving extramedullary relapse.
Huang L; Zhang M; Wei G; Zhao H; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):151-159. PubMed ID: 36161297
[TBL] [Abstract][Full Text] [Related]
35. Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy.
Berger SC; Fehse B; Akyüz N; Geffken M; Wolschke C; Janson D; Gagelmann N; Luther M; Wichmann D; Frenzel C; Thayssen G; Alegiani A; Badbaran A; Zeschke S; Dierlamm J; Kröger N; Ayuk FA
Haematologica; 2023 Feb; 108(2):444-456. PubMed ID: 35950534
[TBL] [Abstract][Full Text] [Related]
36. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
Front Immunol; 2022; 13():997589. PubMed ID: 36131934
[TBL] [Abstract][Full Text] [Related]
37. Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy.
Satyanarayan S; Spiegel J; Hovsepian D; Markert M; Thomas R; Muffly L; Miklos D; Graber K; Scott BJ
Neurohospitalist; 2023 Jan; 13(1):53-60. PubMed ID: 36531846
[TBL] [Abstract][Full Text] [Related]
38. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy.
Amidi Y; Eckhardt CA; Quadri SA; Malik P; Firme MS; Jones DK; Jain A; Danish HH; Rubin DB; Jacobson CA; Cash SS; Lee JW; Dietrich J; Westover MB
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450377
[TBL] [Abstract][Full Text] [Related]
39. A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma.
He P; Liu H; Zimdahl B; Wang J; Luo M; Chang Q; Tian F; Ni F; Yu D; Liu H; Chen L; Wang H; Zhang M; Grupp SA; Liu C
J Cancer Res Clin Oncol; 2023 Jul; 149(7):2757-2769. PubMed ID: 35776199
[TBL] [Abstract][Full Text] [Related]
40. Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma.
De Philippis C; Mannina D; Giordano L; Costantini E; Marcheselli S; Mariotti J; Sarina B; Taurino D; Santoro A; Bramanti S
Transplant Cell Ther; 2023 Jul; 29(7):429.e1-429.e6. PubMed ID: 36966874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]